POINT Biopharma Global Inc.
POINT Biopharma Global Inc.（PNT）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · PNT · 截至 2026年6月9日
活动摘要
买入笔数
8
P-Purchase only
卖出笔数
1
近12个月
买卖比
8.00
Buy/Sell (by trades)
整体情绪
POINT Biopharma Global Inc.内部人在过去近12个月净买入股份，可能反映对公司前景的信心。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
PNT 季度内部人买卖趋势
PNT 内幕交易卖出 · PNT 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
近期内幕交易记录
PNT 高管卖出股份 · PNT 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Dec 26, 2023 | GOODMAN JONATHAN R. Director | Other | 41,872 | $523K | Form 4 |
| Dec 22, 2023 | MCCANN JOE A. CEO · Director | Other | 3,494,153 | $43.68M⚡ | Form 4 |
| Dec 22, 2023 | FLESHNER NEIL E. Chief Medical Officer · Director | Other | 358 | $4K | Form 4 |
| Dec 26, 2023 | HOGUE GERALD L. Director | Other | 21,596 | $270K | Form 4 |
| Dec 26, 2023 | Malik Rajesh Director | Other | 3,700 | $46K | Form 4 |
| Dec 26, 2023 | Lubner David Charles Director | Other | 35,400 | $443K | Form 4 |
| Dec 27, 2023 | Lubner David Charles Director | Other | 3,600 | $45K | Form 4 |
| Dec 22, 2023 | SILBER ALLAN C Executive Chairman · Director | Other | 71,744 | $897K | Form 4 |
| Dec 27, 2023 | MARGOLIN YAEL Director | Other | 1,710 | $21K | Form 4 |
| Nov 6, 2023 | MCCANN JOE A. CEO · Director | Gift | 120,000 | — | Form 4 |
| Nov 3, 2023 | SILBER ALLAN C Executive Chairman · Director | Gift | 500,000 | — | Form 4 |
| Oct 31, 2023 | FLESHNER NEIL E. Chief Medical Officer · Director | Gift | 250,000 | — | Form 4 |
| Mar 21, 2023 | HOGUE GERALD L. Director | Option | 17,936 | $125K | Form 4 |
| Nov 29, 2022 | MCCANN JOE A. CEO | Purchase | 2,160 | $14K | Form 4 |
| Nov 23, 2022 | Lubner David Charles Director | Purchase | 3,600 | $25K | Form 4 |
| Nov 25, 2022 | HOGUE GERALD L. Director | Purchase | 3,660 | $25K | Form 4 |
| Nov 28, 2022 | Malik Rajesh Director | Purchase | 3,700 | $25K | Form 4 |
| Nov 21, 2022 | MARGOLIN YAEL Director | Purchase | 1,710 | $11K | Form 4 |
| Nov 18, 2022 | GOODMAN JONATHAN R. Director | Purchase | 6,000 | $38K | Form 4 |
| Nov 18, 2022 | SILBER ALLAN C Executive Chairman | Purchase | 22,397 | $146K | Form 4 |
| Nov 17, 2022 | SILBER ALLAN C Executive Chairman | Purchase | 27,603 | $166K | Form 4 |
| May 25, 2022 | FLESHNER NEIL E. Chief Medical Officer | Sale | 564,204 | $4.24M⚡ | Form 4 |
FLESHNER NEIL E.
Chief Medical Officer · Director
日期
Dec 22
股数
358
均价
$12.50
总金额
$4K
SILBER ALLAN C
Executive Chairman · Director
日期
Dec 22
股数
71,744
均价
$12.50
总金额
$897K
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 PNT 内幕交易
PNT 内幕交易
POINT Biopharma Global Inc.（PNT）内幕交易数据来源于公司内部人（包括PNT）提交的SEC Form 4申报文件。过去12个月内，0位内部人向SEC提交了交易申报。PNT内部人近期主要在买入，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看POINT Biopharma Global Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
PNT 内幕交易 · 5个问题POINT Biopharma Global Inc.（PNT）的内部人包括高管和董事，如PNT等。过去12个月内，0位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026